Tridek-One closes a €16m financing round led by Pureos Bioventures
Tridek-One SAS, a biotech start-up specialised in the research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16.1m) financing round led by the Swiss VC Pureos Bioventures. New investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), as well as historical investors